Hepatitis B Vaccination in People Living with HIV: Bridging the Immunological Gap
Vaccines · 16.07.2026 · 14 (7) · 623
DOI: 10.3390/vaccines14070623 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 16.07.2026. Verfasst von Christelle Radi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Devision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Hepatitis B virus (HBV) infection remains a major driver of liver-related morbidity and mortality among people living with HIV (PLWH), yet vaccine-induced protection is frequently suboptimal. HIV-associated immune dysfunction, including CD4+ T-cell depletion, altered antigen presentation, impaired T follicular helper cell support, and B-cell dysregulation, reduces seroprotection after standard recombinant HBV vaccines and may limit durability of antibody responses. Vaccine response is further influenced by HIV viral suppression, age, comorbidities, prior vaccine history, and baseline HBV serologic status, including isolated hepatitis B core antibody (anti-HBc) and occult HBV infection (OBI) considerations. Although antiretroviral therapy (ART) improves vaccine responsiveness, many PLWH fail to achieve protective hepatitis B surface antibody (anti-HBs) titers (≥10 mIU/mL) after conventional schedules, or experience antibody waning over time. Current guidelines recommend HBV vaccination for all susceptible PLWH with post-vaccination serologic testing and revaccination for nonresponders. Persistent implementation barriers, including incomplete series, vaccine hesitancy, stigma, and logistical constraints, continue to limit real-world impact. Emerging clinical trial data support CpG-adjuvanted HBV vaccines (HepB-CpG/Heplisav-B) and intensified dosing and schedules (double-dose or four-dose regimens) to improve seroprotection and generate higher peak anti-HBs titers, which may enhance durability. This review synthesizes guideline recommendations, immunologic mechanisms of hyporesponsiveness, predictors of vaccine response, and practical strategies to optimize HBV vaccination in PLWH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Devision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Division of Infectious Diseases, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Center for Vaccinology, University Hospitals of Geneva, 1211 Geneva, Switzerland.
- Center for Vaccinology, University of Geneva, 1211 Geneva, Switzerland.
ORCID-Profile: Daniel J Gromer, Diane Saint-Victor, Suha Kalash
Förderung
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Radi, C., Abu Faraj, J., Idriss, J., Gromer, D. J., Saint-Victor, D., Eberhardt, C. S., Rouphael, N., & Kalash, S. (2026). Hepatitis B Vaccination in People Living with HIV: Bridging the Immunological Gap. Vaccines, 14(7), 623. https://doi.org/10.3390/vaccines14070623
Vancouver
Radi C, Abu Faraj J, Idriss J, Gromer DJ, Saint-Victor D, Eberhardt CS, et al. Hepatitis B Vaccination in People Living with HIV: Bridging the Immunological Gap. Vaccines. 2026;14(7):623. doi:10.3390/vaccines14070623
BibTeX
@article{Radi2026,
author = {Radi, Christelle and Abu Faraj, Jana and Idriss, Jad and Gromer, Daniel J and Saint-Victor, Diane and Eberhardt, Christiane S and Rouphael, Nadine and Kalash, Suha},
title = {Hepatitis B Vaccination in People Living with HIV: Bridging the Immunological Gap},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {7},
pages = {623},
doi = {10.3390/vaccines14070623}
}
EUVIMED